LAUSR

Cancer Acute myeloid leukemia is an aggressive cancer that can be difficult to treat because of rapidly evolving therapeutic resistance. Melgar et al. focused on a subtype of acute myeloid leukemia characterized by mutations in a receptor gene FLT3 . Although FLT3 inhibitors can target oncogenic signaling pathways in this cancer, their effects do not last. The authors identified a pathway involved in the innate immune stress response whose activation promoted resistance to drugs targeting the FLT3 pathway, then they developed an inhibitor that targets both pathways at once. This multikinase inhibitor showed promising results in vitro and in animals. Sci. Transl. Med. 11 , eaaw8828 (2019).